This study through Shandong University is an open-label randomized phase 2 study involving multiple sites looking at the immunomodulation effect of using high-dose dexamethasone alone vs in combination with Diammonium Glycyrrhizinate, a Chinese Herbal Medicinal salt that is believed to have anti-inflammatory, antioxidant, and hepatoprotective properties. Inclusion criteria is restricted to participants who have not received ITP treatment in past and are between the ages of 18-80 years. Participants must also have a platelet count less than 30,000 µL. Individuals who have secondary ITP or an immune deficiency (severe) will not be eligible to participate. Individuals with common comorbidities such as inflammatory bowel, hypertension, diabetes, and pregnancy will also be excluded from participation.